Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pulmonary Disease, Chronic Obstructive: later-stage trial registry
7 of 75 indexed Pulmonary Disease, Chronic Obstructive trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #178 of 28,707 conditions by registered trial count.
75 US clinical trials · 7 currently recruiting · #178 of 28,707 conditions by registered trial count
Pulmonary Disease, Chronic Obstructive: 75 US clinical trials tracked, 7 recruiting.
Pulmonary Disease, Chronic Obstructive is the subject of 75 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 34 are in Phase 3-4 (later-stage) and 20 in Phase 1-2 (earlier-stage). The most active sponsor is GlaxoSmithKline, running 30 of these trials.
Enrollment posture brief
Registry condition pulmonary-disease-chronic-obstructive
OPEN 7 | RECR 9% | LATE 34 | EARLY 20 | RANK #178 | SPON 30
Volume-matched condition peers
Nearest open-share peer: Visual Acuity (10% recruiting · 21 trials)
Pulmonary Disease, Chronic Obstructive lists 7 open slots (9% of 75 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pulmonary Disease, Chronic Obstructive on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pulmonary Disease, Chronic Obstructive is recruiting below its size-band peers.
7 of 75 indexed trials (9.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Pulmonary Disease, Chronic Obstructive research.
GlaxoSmithKline accounts for 30 of 75 trials (40%). 29 distinct sponsors appear on at least one study for this condition label.
-
Typical Pulmonary Disease, Chronic Obstructive enrolment sits around 295 participants.
Median target enrolment is 295 among the 75 trials that report a genuine target (sentinel values excluded). 22 of those (29.3%) plan for fewer than 100 participants.
-
Pulmonary Disease, Chronic Obstructive research is mostly interventional.
66 interventional and 9 observational studies make up this index (88% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
75 total, page 1 of 2
Pragmatic Trial to Enhance Quality Safety, and Patient Experience in COPD
Seattle Institute for Biomedical and Clinical Research
NCT05718102
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
GlaxoSmithKline
NCT07177339
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
GlaxoSmithKline
NCT06959095
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
GlaxoSmithKline
NCT06961214
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
GlaxoSmithKline
NCT06154837
The ROAM Research Study Therapy (LTOT) Version
University of Virginia
NCT06810323
Trial to Determine Effective Aspirin Dose in COPD
Johns Hopkins University
NCT05265299
Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD)
Brigham and Women's Hospital
NCT00608764
Air Filtration for COPD in VA Population of Veterans
Illinois Institute of Technology
NCT05913765
Evaluating the Clinical Effectiveness of a Patient-specific Silicone Stent
VisionAir Solutions
NCT05050591
A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline
NCT02164513
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.
Boehringer Ingelheim
NCT02296138
Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline
NCT00268216
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
Boehringer Ingelheim
NCT00144339
EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)
AstraZeneca
NCT07103642
Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
Boehringer Ingelheim
NCT01431274
Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1)
University of Washington
NCT04281784
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
GlaxoSmithKline
NCT01313637
Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy
GlaxoSmithKline
NCT00791518
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease
GlaxoSmithKline
NCT02207829
Tiotropium / Respimat One-Year Study
Boehringer Ingelheim
NCT00168831
Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
Novartis Pharmaceuticals
NCT04072887
24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease
GlaxoSmithKline
NCT01316900
A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline
NCT01706328
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
Boehringer Ingelheim
NCT02006732
Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations
GlaxoSmithKline
NCT00115492
Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide
Pfizer
NCT01543919
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
GlaxoSmithKline
NCT01110200
Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks
GlaxoSmithKline
NCT01772134
A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline
NCT00606684
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline
NCT00676052
CT-Based Modeling of Bone Micro-Architecture and Fracture-Risk in COPD
Punam K Saha
NCT03534934
Multidisciplinary Inpatient Palliative Care Intervention
Kaiser Permanente
NCT00325611
Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline
NCT01323621
Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.
Boehringer Ingelheim
NCT00452400
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
Pfizer
NCT00808288
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Boehringer Ingelheim
NCT00696020
Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component
GlaxoSmithKline
NCT02164539
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
Boehringer Ingelheim
NCT00388882
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
GlaxoSmithKline
NCT01323660
To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways
Boehringer Ingelheim
NCT02085161
Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD
Eli Lilly and Company
NCT00157339
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients
Boehringer Ingelheim
NCT01533922
Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease
Mereo BioPharma
NCT02700919
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
GlaxoSmithKline
NCT02586493
Evaluating Genetic Factors That May Contribute to Elastin Function and the Development of Chronic Obstructive Pulmonary Disease
Washington University School of Medicine
NCT00725309
A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline
NCT00857766
Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)
GlaxoSmithKline
NCT00633217
Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline
NCT03227445
An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients
GlaxoSmithKline
NCT02799784
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 13 |
| Phase 3 | 22 |
| Phase 4 | 12 |
Top Sponsors
Named interventions
Most-linked intervention names on Pulmonary Disease, Chronic Obstructive records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pulmonary Disease, Chronic Obstructive trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pulmonary Disease, Chronic Obstructive page
75 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Pulmonary Disease, Chronic Obstructive trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- GlaxoSmithKline sponsors the most Pulmonary Disease, Chronic Obstructive trials on record, review their full trial history before evaluating a specific study. See GlaxoSmithKline's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pulmonary Disease, Chronic Obstructive condition card totals 75 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.